University of Wisconsin–Madison

Tag: biomarkers

Reflecting on 25 Years of the Wisconsin Registry for Alzheimer’s Prevention

Posted on

Twenty-five years ago, a single participant enrolled in what would become the Wisconsin Registry for Alzheimer’s Prevention (WRAP), now one of the largest and longest-running studies of Alzheimer’s risk in the world. To celebrate this milestone, we’re joined by Dr. Mark Sager, who co-founded WRAP, along with current multi-principal investigators Dr. Sterling Johnson and Dr. Jessica Caldwell, to discuss how the study has evolved, the discoveries that have reshaped our understanding of Alzheimer’s prevention, and what the next 25 years may hold for the field. 

Guests: Mark Sager, MD, founder, Wisconsin Alzheimer’s Institute (WAI), WRAP, Sterling Johnson, PhD, multi-principal investigator, WRAP, associate director, Wisconsin Alzheimer’s Disease Research Center, WAI, Jessica Caldwell, multi-principal investigator, WRAP, visiting associate professor, department of neurology, University of Wisconsin-Madison

Study Finds COVID-19 Can Cause Build-up of Alzheimer’s-Related Proteins in Eyes and Brain

Posted on

What do COVID-19 brain fog and ophthalmology have to do with Alzheimer’s disease? There may be more connections than one might think. Dr. Sean Miller is one of the scientists behind a recent study that used retinal tissue to investigate the links between COVID-19 infections and the build-up of amyloid and other indicators of Alzheimer’s disease in the central nervous system. Dr. Miller joins the podcast to discuss his research and its implications for COVID and dementia diagnosis and treatments in the future.

Guest: Sean Miller, PhD, research scientist, department of ophthalmology and visual science, Yale School of Medicine

LATE, Explained

Posted on

While there are many kinds of dementia, like Alzheimer’s disease and Lewy body dementia, there’s one that researchers have only recently identified. LATE, or Limbic-predominant Age-related TDP-43 Encephalopathy, is a newly-characterized type of dementia associated with abnormal clumps of a protein called TDP-43. So, what exactly do we know about LATE? Dr. David Wolk joins the podcast to share what key features of LATE are, how it compares to Alzheimer’s disease and impacts treatment, and what next steps are needed to better understand this neurodegenerative disease.

Guest: David Wolk, MD, director, Penn Alzheimer’s Disease Research Center, co-director, Penn Memory Center, co-director, Penn Institute on Aging, chief, Division of Cognitive Neurology, professor of neurology, University of Pennsylvania Perelman School of Medicine

The Future of Fluid Biomarkers for Alzheimer’s Disease and Related Dementias

Posted on

The field of biomarkers is constantly evolving, leading to developments in diagnosing and treating different kinds of dementia, but what exactly are biomarkers and how has our understanding of these measures changed over time?  Dr. Henrik Zetterberg joins Dementia Matters to talk about the latest updates in research on fluid biomarkers. Dr. Zetterberg goes in depth on the role and properties of different biomarkers and how new measures and tools, like blood tests, are impacting diagnostic tests for Alzheimer’s and other neurodegenerative diseases.

Guest: Henrik Zetterberg, MD, PhD, professor of neurochemistry, University of Gothenburg, University College London, visiting professor, University of Wisconsin–Madison, Biomarker Core co-leader, Wisconsin Alzheimer’s Disease Research Center

Could Green Tea Hold the Key to New Alzheimer’s Treatments?

Posted on

Dr. Paul Seidler joins the podcast to discuss his recent study looking at the connection between molecules in green tea and tau proteins. He also discusses the impact those molecules have on preventing cognitive decline and how these findings could lead to new strategies for treating Alzheimer’s disease.

Guest: Paul Seidler, PhD, assistant professor, University of Southern California Mann School of Pharmacy and Pharmaceutical Sciences

Highlights from the 2023 Alzheimer’s Association International Conference

Posted on

The 2023 Alzheimer’s Association International Conference (AAIC) in Amsterdam brought together the world’s leading scientists, clinical researchers, early career investigators, caregiving researchers and more to discuss the latest findings and advancements in dementia science. Dr. Percy Griffin joins the podcast to share key highlights from the conference. He discusses the use of CRISPR technology in Alzheimer’s research, the significance of defining Alzheimer’s by its biology rather than its symptoms and how the field is moving toward a precision medicine approach. 

Guest: Percy Griffin, PhD, director of scientific engagement, Alzheimer’s Association

Studies Look at Generational Differences and Associations between Cognition, Sensory Changes and Blood Biomarkers

Posted on

Dr. Natascha Merten joins the podcast to discuss her study focused on trends in cognitive function across generations. Merten also explains her research on the associations between sensory and motor functions and blood-based biomarkers for neurodegeneration and dementia.

Guest: Natascha Merten, PhD, MS, director, Beaver Dam Offspring Study-Neurocognitive Aging Study, assistant professor, Departments of Population Health Sciences and Medicine, University of Wisconsin–Madison

Disclosing Alzheimer’s Disease Biomarker Results in Diverse Populations

Posted on

Dr. Annalise Rahman-Filipiak joins the podcast to discuss her research focused on disclosing neuroimaging biomarkers across diverse populations. She addresses why some people might want to know their biomarker results, while others might not, and how careful disclosure of these results to at-risk individuals may help prepare them and their families for the future through personalized treatment, research engagement, advanced planning and emotional support.

Guest: Annalise Rahman-Filipiak, PhD, assistant professor, neuropsychologist, department of psychiatry, University of Michigan

Looking Toward the Future: How Preclinical Alzheimer’s Disease Biomarker Disclosures Impact Society

Posted on

The field of biomarkers is advancing quickly, allowing preclinical Alzheimer’s disease to be identified earlier and earlier in a person’s life. As individuals learn they are at risk for Alzheimer’s years or even decades before experiencing cognitive decline, what does this mean for them and for society as a whole? Drs. Emily Largent and Claire Erickson join the podcast to discuss ten key areas, such as healthcare, insurance, and direct-to-consumer testing, that should be addressed to support those at risk for cognitive decline and broader U.S. society as biomarker testing and disclosures become more prominent.

Guests: Emily Largent, PhD, RN, Emanuel and Robert Hart Assistant Professor, University of Pennsylvania Perelman School of Medicine, and Claire Erickson, PhD, MPA, postdoctoral fellow, University of Pennsylvania Perelman School of Medicine

The Case for Disclosing Biomarker Results to Alzheimer’s Research Participants

Posted on

Though several validated biomarkers are studied and used in Alzheimer’s disease research, most research participants don’t have the opportunity to learn their biomarker results afterward, even if they have cognitive impairment. Drs. Jason Karlawish and Josh Grill join the podcast to discuss the debate over sharing biomarker results with research participants, how these powerful disclosures can be made ethically, and why it’s as important for the field to study biomarker disclosures as it is to study the biomarkers themselves.

Guests: Josh Grill, PhD, director, Institute for Memory Impairments and Neurological Disorders, associate professor, University of California, Irvine, and Jason Karlawish, MD, co-director, Penn Memory Center, professor of medicine, medical ethics and health policy, and neurology, University of Pennsylvania

Update on Blood Tests for Alzheimer’s Disease

Posted on

Research in the field of fluid biomarkers is leading to new developments in Alzheimer’s disease identification, including new tests that can predict Alzheimer’s based on biomarkers in blood. Ahead of his keynote address as part of Alzheimer’s Disease & Related Dementias Research Day on April 5, 2022, Dr. Thomas Karikari joins the podcast to discuss his work with these new blood tests, how accurate they are, and what research needs to be done before they are made available for clinical use.

Guest: Thomas Karikari, PhD, assistant professor, University of Gothenburg, University of Pittsburgh

Harnessing the Power of Autophagy to Treat Alzheimer’s Disease

Posted on

The Puglielli lab at the University of Wisconsin School of Medicine and Public Health has found a way to manipulate autophagy — a process where cells clean out damaged materials — to rid the brain of toxic proteins like amyloid and tau. Researchers hope to use the power of this process to develop future treatments for Alzheimer’s disease and other diseases of aging. Luigi Puglielli joins the podcast to discuss his team’s research over the past 15 years, why the scientific process can take years to turn ideas into possible treatments, and how he hopes this research can be used in the future.

Guest: Luigi Puglielli, MD, PhD, professor of medicine, University of Wisconsin School of Medicine and Public Health

Safely Disclosing Amyloid Results with Alzheimer’s Disease Research Participants

Posted on

Dr. Lindsay Clark’s new study will evaluate the psychological consequences of disclosing amyloid test results to cognitively unimpaired adults. Dr. Clark joins the podcast to define amyloid accumulation and discuss how her study will examine the process of revealing amyloid results to research participants in Alzheimer’s disease research studies.

Guest: Lindsay Clark, PhD, assistant professor, University of Wisconsin School of Medicine and Public Health

Bonus Episode: Current Research into Frontotemporal Dementia

Posted on

In this bonus episode, we continue our conversation with Dr. Howie Rosen on Frontotemporal Dementia (FTD). On last week’s episode, Dr. Rosen spoke on the genetic risk factors, trajectories and family caregiving experiences of FTD. Now, our conversation turns to the research looking into how the disease affects self-awareness, biomarkers and early detection, as well as ways people can volunteer for a research study.

Guest: Howard “Howie” Rosen, MD, behavioral neurologist at the University of California San Francisco Memory and Aging Center

How Biomarkers and Brain Imaging Are Used to Detect Early Stages of Alzheimer’s Disease

Posted on

Alzheimer’s disease-related changes occur in the brain more than 15 years before a person experiences the memory and personality changes associated with the disease. By studying the disease in its earliest stages, scientists hope to find treatments that can prevent or delay the onset of dementia and memory loss.

Guest: Sterling Johnson, PhD, Clinical Neuropsychologist, Professor of Geriatrics, University of Wisconsin School of Medicine and Public Health, Associate Director of the Wisconsin Alzheimer’s Disease Research Center, Principle Investigator of the Wisconsin Registry for Alzheimer’s Prevention (WRAP) Study